Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1994 1
1996 1
1998 1
1999 1
2000 9
2001 5
2002 12
2003 7
2004 5
2005 11
2006 18
2007 19
2008 15
2009 20
2010 15
2011 9
2012 17
2013 14
2014 13
2015 8
2016 8
2017 14
2018 11
2019 6
2020 11
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

244 results
Results by year
Filters applied: . Clear all
Page 1
Behçet syndrome: a contemporary view.
Yazici H, Seyahi E, Hatemi G, Yazici Y. Yazici H, et al. Among authors: yazici y. Nat Rev Rheumatol. 2018 Feb;14(2):107-119. doi: 10.1038/nrrheum.2017.208. Epub 2018 Jan 3. Nat Rev Rheumatol. 2018. PMID: 29296024 Review.
Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Hatemi G, et al. Among authors: yazici y. N Engl J Med. 2019 Nov 14;381(20):1918-1928. doi: 10.1056/NEJMoa1816594. N Engl J Med. 2019. PMID: 31722152 Clinical Trial.
Editorial: Introduction, vasculitis 2020.
Yazici H, Yazici Y. Yazici H, et al. Among authors: yazici y. Curr Opin Rheumatol. 2020 Jan;32(1):1-2. doi: 10.1097/BOR.0000000000000675. Curr Opin Rheumatol. 2020. PMID: 31789993 No abstract available.
The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
Tam BY, Chiu K, Chung H, Bossard C, Nguyen JD, Creger E, Eastman BW, Mak CC, Ibanez M, Ghias A, Cahiwat J, Do L, Cho S, Nguyen J, Deshmukh V, Stewart J, Chen CW, Barroga C, Dellamary L, Kc SK, Phalen TJ, Hood J, Cha S, Yazici Y. Tam BY, et al. Among authors: yazici y. Cancer Lett. 2020 Mar 31;473:186-197. doi: 10.1016/j.canlet.2019.09.009. Epub 2019 Sep 24. Cancer Lett. 2020. PMID: 31560935 Free article.
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V, O'Green AL, Bossard C, Seo T, Lamangan L, Ibanez M, Ghias A, Lai C, Do L, Cho S, Cahiwat J, Chiu K, Pedraza M, Anderson S, Harris R, Dellamary L, Kc S, Barroga C, Melchior B, Tam B, Kennedy S, Tambiah J, Hood J, Yazici Y. Deshmukh V, et al. Among authors: yazici y. Osteoarthritis Cartilage. 2019 Sep;27(9):1347-1360. doi: 10.1016/j.joca.2019.05.006. Epub 2019 May 25. Osteoarthritis Cartilage. 2019. PMID: 31132406 Free article.
A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.
Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L, Stewart J, Chiu K, Ibanez M, Pedraza M, Seo T, Do L, Cho S, Cahiwat J, Tam B, Tambiah JRS, Hood J, Lane NE, Yazici Y. Deshmukh V, et al. Among authors: yazici y. Osteoarthritis Cartilage. 2018 Jan;26(1):18-27. doi: 10.1016/j.joca.2017.08.015. Epub 2017 Sep 6. Osteoarthritis Cartilage. 2018. PMID: 28888902 Free article.
Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Yazici Y, et al. Arthritis Rheumatol. 2020 Oct;72(10):1694-1706. doi: 10.1002/art.41315. Epub 2020 Sep 6. Arthritis Rheumatol. 2020. PMID: 32432388 Free PMC article. Clinical Trial.
Management of Behçet syndrome.
Yazici Y. Yazici Y. Curr Opin Rheumatol. 2020 Jan;32(1):35-40. doi: 10.1097/BOR.0000000000000666. Curr Opin Rheumatol. 2020. PMID: 31609785 Review.
Behçet's syndrome.
Hatemi G, Yazici Y, Yazici H. Hatemi G, et al. Among authors: yazici y. Rheum Dis Clin North Am. 2013 May;39(2):245-61. doi: 10.1016/j.rdc.2013.02.010. Epub 2013 Mar 14. Rheum Dis Clin North Am. 2013. PMID: 23597962 Review.
Biomarkers in vasculitis.
Hatemi G, Esatoglu SN, Yazici Y. Hatemi G, et al. Among authors: yazici y. Curr Opin Rheumatol. 2018 Jan;30(1):30-35. doi: 10.1097/BOR.0000000000000447. Curr Opin Rheumatol. 2018. PMID: 28937415 Review.
244 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page